Profs Domenica Lorusso and Jean-Sebastien Frenel share expert insights on the PYNNACLE Phase 2 interim analysis at ESGO 2026. The PYNNACLE study evaluates rezatapopt*, a first-in-class p53 reactivator, in TP53 Y220C–mutant advanced solid tumours, including ovarian cancer.

 

In this video, the experts discuss: 

  • TP53, the Y220C variant, and the rationale for mutant p53 reactivation 
  • Study overview and practice implications, spotlighting ovarian cancer 
  • Testing strategies for early and accurate patient identification 

 

Clinical takeaways

  • Rezatapopt is a first-in-class investigational p53 reactivator that selectively binds to the mutated p53 Y220C protein, stabilising its structure to restore wild-type tumour suppressor activity   
  • Rezatapopt demonstrates rapid, durable and broad antitumour activity in heavily pretreated patients with TP53 Y220C-mutated advanced ovarian cancer, where effective targeted therapies and biomarkers are limited  
  • Looking ahead, it will be important to prioritise early and accurate identification through up-front comprehensive genomic profiling using NGS with TP53 gene coverage. Tissue is preferred; when tissue is limited, selected ctDNA assays capable of excluding CHIP may be used 

 

*Rezatapopt is an investigational agent which is not approved by a regulatory agency

  • Educate on the role of TP53 as a tumour suppressor gene, its mutation in cancer, and the significance of the Y220C variant​
  • Highlight the importance of treating cancers based on genomic mutations​
  • Emphasise the need for genomic testing to identify patients with the TP53 Y220C mutation​
  • Educate clinicians on the ongoing clinical trials, such as the PYNNACLE trial

Prof. Domenica "Ketta" Lorusso obtained her degree in Medicine and Surgery in 1995, her residency in Obstetrics and Gynecology in 1999 and her PhD in Obstetrics and Gynecology in 2003. She is currently Associate Professor of Obstetrics and Gynecology at the Catholic University of Rome and responsible for clinical research at Fondazione Policlinico Gemelli IRCCS.

She is an active member of the European Network of Gynaecological Oncological Trial groups (ENGOT), where she leads the Gynecological Cancer Academy (since 2020). Dr Lorusso is a member of the Board of Directors of the Gynecologic Cancer InterGroup (GCIG), where she is the past chair of the Endometrial Cancer Committee and the Nomination and Meeting Committee. Currently, she is a member of the ESGO Council and scientific coordinator of the ESMO Gynaecological Cancers Congress. She is involved in preclinical and clinical research in gynaecological cancer, and she is the author of more than 250 papers on gynaecological cancers. Her work has hugely contributed to improving the quality of care and clinical outcome and to reducing the toxicity of treatments in women with advanced gynaecological malignancies.

Prof. Domenica Lorusso has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

MSD, GSK, Novartis, Clovis Oncology, AstraZeneca, Eisai, PharmaMar, ImmunoGen, Genmab

Prof. Frenel is a Medical Oncologist at the Institut de Cancerologie de L’Ouest in Nantes France. He is a professor of medicine at Nantes University and a member of the Board of the GINECO group.

Prof. Jean-Sebastien Frenel has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astra Zeneca, GSK, Esai, MSD, Lilly, Pfizer, Novartis, Daichi Sankyon, Seagen, ABBVIE, ROCHE, Pharma End, Boehringer

Profs Domenica Lorusso and Jean-Sebastien Frenel share expert insights on the PYNNACLE Phase 2 interim analysis at ESGO 2026. The PYNNACLE study evaluates rezatapopt*, a first-in-class p53 reactivator, in TP53 Y220C–mutant advanced solid tumours, including ovarian cancer.

 

In this video, the experts discuss: 

  • TP53, the Y220C variant, and the rationale for mutant p53 reactivation 
  • Study overview and practice implications, spotlighting ovarian cancer 
  • Testing strategies for early and accurate patient identification 

 

Clinical takeaways

  • Rezatapopt is a first-in-class investigational p53 reactivator that selectively binds to the mutated p53 Y220C protein, stabilising its structure to restore wild-type tumour suppressor activity   
  • Rezatapopt demonstrates rapid, durable and broad antitumour activity in heavily pretreated patients with TP53 Y220C-mutated advanced ovarian cancer, where effective targeted therapies and biomarkers are limited  
  • Looking ahead, it will be important to prioritise early and accurate identification through up-front comprehensive genomic profiling using NGS with TP53 gene coverage. Tissue is preferred; when tissue is limited, selected ctDNA assays capable of excluding CHIP may be used 

 

*Rezatapopt is an investigational agent which is not approved by a regulatory agency

  • Educate on the role of TP53 as a tumour suppressor gene, its mutation in cancer, and the significance of the Y220C variant​
  • Highlight the importance of treating cancers based on genomic mutations​
  • Emphasise the need for genomic testing to identify patients with the TP53 Y220C mutation​
  • Educate clinicians on the ongoing clinical trials, such as the PYNNACLE trial

Prof. Frenel is a Medical Oncologist at the Institut de Cancerologie de L’Ouest in Nantes France. He is a professor of medicine at Nantes University and a member of the Board of the GINECO group.

Prof. Jean-Sebastien Frenel has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astra Zeneca, GSK, Esai, MSD, Lilly, Pfizer, Novartis, Daichi Sankyon, Seagen, ABBVIE, ROCHE, Pharma End, Boehringer

Prof. Domenica "Ketta" Lorusso obtained her degree in Medicine and Surgery in 1995, her residency in Obstetrics and Gynecology in 1999 and her PhD in Obstetrics and Gynecology in 2003. She is currently Associate Professor of Obstetrics and Gynecology at the Catholic University of Rome and responsible for clinical research at Fondazione Policlinico Gemelli IRCCS.

She is an active member of the European Network of Gynaecological Oncological Trial groups (ENGOT), where she leads the Gynecological Cancer Academy (since 2020). Dr Lorusso is a member of the Board of Directors of the Gynecologic Cancer InterGroup (GCIG), where she is the past chair of the Endometrial Cancer Committee and the Nomination and Meeting Committee. Currently, she is a member of the ESGO Council and scientific coordinator of the ESMO Gynaecological Cancers Congress. She is involved in preclinical and clinical research in gynaecological cancer, and she is the author of more than 250 papers on gynaecological cancers. Her work has hugely contributed to improving the quality of care and clinical outcome and to reducing the toxicity of treatments in women with advanced gynaecological malignancies.

Prof. Domenica Lorusso has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

MSD, GSK, Novartis, Clovis Oncology, AstraZeneca, Eisai, PharmaMar, ImmunoGen, Genmab

Programme summary
Watch the video now
Share this programme
This programme has been sponsored by PMV Pharma and is intended for HCPs only.
Supporter Acknowledgement
This programme has been sponsored by PMV Pharma and is intended for HCPs only.
I agree that this programme:

Was valuable to me

1/3
Programme summary
Share this programme
This programme has been sponsored by PMV Pharma and is intended for HCPs only.
Supporter Acknowledgement
This programme has been sponsored by PMV Pharma and is intended for HCPs only.
I agree that this programme:

Was valuable to me

1/3

Other programmes of interest

conference-update Conference update
Oncology 
Coming soon! Oncogene-addicted NSCLC highlights from ELCC 2026

Expert insights on the latest NSCLC data

Experts
Prof. Nicolas Girard
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
ISLB Lung Cancer Europe
  • clock 1 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Video podcast
Oncology 
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Experts
Dr Carlos Barrios, Prof. Gary Tse, Oncology Brothers (Moderators)
Endorsed by
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Daiichi Sankyo 
eks
EKS / On-demand webinar
Oncology 
Multiple Myeloma: Is it time to rethink how we sequence treatments?

On-demand materials from an Experts Knowledge Share event

Experts
Prof. Karthik Ramasamy, Dr Joshua Richter, Dr Faisal Basheer, Dr Andrew Charlton
  • download Downloadable
    Resources
  • clock 80 MIN
  • calendar Mar 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs in the UK only    MAT-GB-SEL-00774
conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
patient-support Patient Support
Oncology Hemato-oncology Pediatrics 
Personalised treatment in childhood cancer: A journey through NTRK fusion testing

Experts
Linet Menachery
Endorsed by
NTRKers ICAN international cancer advocacy network Biomarker Collaborative
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.